Amereh Meitham, Shojaei Shahla, Seyfoori Amir, Walsh Tavia, Dogra Prashant, Cristini Vittorio, Nadler Ben, Akbari Mohsen
Department of Mechanical Engineering, University of Victoria, 3800 Finnerty Road, Victoria, V8P 5C2, BC, Canada.
Laboratory for Innovations in MicroEngineering (LiME), University of Victoria, 3800 Finnerty Road, Victoria, V8P 5C2, BC, Canada.
Commun Eng. 2024 Nov 25;3(1):176. doi: 10.1038/s44172-024-00319-9.
Non-physiological levels of oxygen and nutrients within the tumors result in heterogeneous cell populations that exhibit distinct necrotic, hypoxic, and proliferative zones. Among these zonal cellular properties, metabolic rates strongly affect the overall growth and invasion of tumors. Here, we report on a hybrid discrete-continuum (HDC) mathematical framework that uses metabolic data from a biomimetic two-dimensional (2D) in-vitro cancer model to predict three-dimensional (3D) behaviour of in-vitro human glioblastoma (hGB). The mathematical model integrates modules of continuum, discrete, and neurons. Results indicated that the HDC model is capable of quantitatively predicting growth, invasion length, and the asymmetric finger-type invasion pattern in in-vitro hGB tumors. Additionally, the model could predict the reduction in invasion length of hGB tumoroids in response to temozolomide (TMZ). This model has the potential to incorporate additional modules, including immune cells and signaling pathways governing cancer/immune cell interactions, and can be used to investigate targeted therapies.
肿瘤内非生理水平的氧气和营养物质导致细胞群体异质性,表现出不同的坏死、缺氧和增殖区域。在这些区域细胞特性中,代谢率强烈影响肿瘤的整体生长和侵袭。在此,我们报告一种混合离散-连续统(HDC)数学框架,该框架使用来自仿生二维(2D)体外癌症模型的代谢数据来预测体外人胶质母细胞瘤(hGB)的三维(3D)行为。该数学模型整合了连续统、离散和神经元模块。结果表明,HDC模型能够定量预测体外hGB肿瘤的生长、侵袭长度和不对称指状侵袭模式。此外,该模型可以预测替莫唑胺(TMZ)处理后hGB类肿瘤侵袭长度的减少。该模型有潜力纳入其他模块,包括免疫细胞和控制癌症/免疫细胞相互作用的信号通路,并可用于研究靶向治疗。
Biomimetics (Basel). 2023-9-11
Neurotherapeutics. 2022-10
Cancer Control. 2022
Cancer Discov. 2022-1
Micromachines (Basel). 2021-6-25
Nat Rev Cancer. 2021-5
PLoS Comput Biol. 2021-1
Trends Cell Biol. 2020-10
Front Oncol. 2020-6-25